Czech Republic Plans to Reduce Tobacco Harm with Nicotine Pouches

Jul.01.2022
Czech Republic Plans to Reduce Tobacco Harm with Nicotine Pouches
Czech Republic to implement a tobacco harm reduction strategy including the use of nicotine pouches, as local leadership attitudes change.

Due to a change in the mentality of local leaders, the Czech Republic will be implementing a strategy aimed at reducing the harm caused by tobacco, which includes the use of nicotine pouches. According to Ondřej Jakob, a spokesperson for the Czech Ministry of Health, a new action plan is currently being discussed and is expected to be implemented in the near future.

 

This issue has yet to be resolved. A new law is being prepared for nicotine pouches to define their composition, appearance, quality, characteristics, and other parameters, in order to minimize their adverse effects on human health." Jakob explained. The new law is expected to consider various factors that need to be taken into account. He said, "At this point, we anticipate debating a new action plan that should set the direction for the next three years, including tobacco addiction.

 

According to ECigIntelligence, successfully implementing harm reduction in the country's next three-year action plan could also promote other safer alternatives, such as electronic cigarettes and nasal snuff. Jakob discussed these products, stating that "electronic cigarettes and heated tobacco products are both controversial.

 

We believe that, in the future, new products should be designed with flavors that mask the unpleasant taste of nicotine while still adhering to harm reduction principles. However, they should be limited as much as possible to attract as few people as possible, especially young people, to avoid creating another batch of nicotine addicts.

 

The threat to teenagers, including risks to their health and the emergence of new addictions, has yet to be resolved and this may also apply to current non-smokers. For this reason, the Czech Republic is currently discussing this issue," he added.

 

The European Union is still spreading the "debunked theory".

 

Meanwhile, the EU Health and Food Safety Commissioner, Stella Kyriakides, questioned the effectiveness of e-cigarettes as a smoking cessation aid and even claimed that they are a gateway to smoking in another statement spreading misinformation about e-cigarettes.

 

Michael Landl, Director of the World Vapers' Alliance (WVA), expressed concern that the European Commission is still disregarding scientific evidence on e-cigarettes. He stated that it is alarming that the Commission continues to promote outdated and debunked theories on e-cigarettes, and systematically ignores vast amounts of scientific evidence that demonstrates their benefits, not to mention the firsthand experiences of millions of e-cigarette users. Compared to traditional therapies like gum or patches, e-cigarettes are 95% less harmful than smoking and a more effective method for quitting. The Commission's approach to e-cigarettes will only result in loss of life.

 

“Overall, it is known that both smokeless and novel tobacco and related products contain nicotine, a toxic and highly addictive substance known to be harmful to health - enhancing nicotine addiction. This is why these products are regulated and, as far as oral tobacco is concerned, banned by the European Union,” the statement concluded.

 

This article is compiled from third-party information sources, and the copyright of the compiled information belongs to the original media and author.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
Australia Tobacco Tax Debate Spreads Within Labor as NSW Premier Minns Reaffirms Support for a Cut
Australia Tobacco Tax Debate Spreads Within Labor as NSW Premier Minns Reaffirms Support for a Cut
Australia’s tobacco excise debate is increasingly exposing differences within the governing Labor Party. New South Wales Labor Premier Chris Minns reaffirmed on September 8 that he supports reducing tobacco excise, arguing that current tax settings are pushing consumers toward cheaper black-market cigarettes. Federal Health Minister Mark Butler continues to oppose an excise cut, while Treasurer Jim Chalmers and Assistant Treasurer Daniel Mulino have recently stopped short of ruling out future changes. The divergence follows the opposition Coalition’s proposal to cut tobacco excise by 80%.
Sep.08
From Product Innovation to Integrated Solutions: NEXTECH Expands Its Global Heated Tobacco Solutions
From Product Innovation to Integrated Solutions: NEXTECH Expands Its Global Heated Tobacco Solutions
NEXTECH launched its NEXE Pro circumferential-heating tobacco stick globally at InterTabac 2026, as the company expands from product innovation into broader heated tobacco solutions. Amid intensifying competition across global HTP markets, NEXTECH is strengthening its R&D, manufacturing and pre-launch support capabilities to serve different types of business customers.
Industry Insight
Sep.15
BAT’s Velo Study Finds 61% of Nicotine Users Feel More Comfortable Expressing Themselves When Others Do the Same
BAT’s Velo Study Finds 61% of Nicotine Users Feel More Comfortable Expressing Themselves When Others Do the Same
British American Tobacco’s (BAT) nicotine pouch brand Velo has released a global consumer study and launched its “Echoes of Tomorrowland” campaign with electronic music festival brand Tomorrowland. The research surveyed 2,009 nicotine users across the UK, Spain, Pakistan, Poland and Austria. Velo said 61% of respondents feel more comfortable expressing themselves when they see others doing the same, while 39% said building meaningful connections becomes harder with age. The campaign reflects how nicotine pouch brands are increasingly using music, communities and lifestyle marketing to build consumer engagement.
Aug.10
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As regulators pay closer attention to child safety in nicotine pouches, manufacturers face a practical challenge: how to strengthen child-resistant packaging without unnecessarily reworking products, production lines and regulatory submissions already in place. In a written interview with 2Firsts, Chemular detailed Safeguard’s external packaging approach, its customer-specific testing requirements and possible PMTA pathways. The model remains early-stage, but it offers a new way to think about an increasingly important regulatory and manufacturing issue.
Industry Insight
Sep.19
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Holdings said in its latest shareholder letter that it is moving to commercialize PACHA products and monetize its PMTA assets as the FDA changes enforcement priorities for unauthorized ENDS products. Thirty PACHA SKUs were previously tentatively identified for a proposed public list of products that the FDA generally does not intend to prioritize for enforcement. Charlie’s is also preparing test-market sales of age-gated flavored disposables and says it currently holds 678 PMTA-related product assets while seeking additional strategic transactions and partnerships.
Sep.11